Literature DB >> 17427270

Localization of bone marrow stromal cells in injured spinal cord treated by intravenous route depends on the hemorrhagic lesions in traumatized spinal tissues.

Ali Reza Khalatbary1, Taki Tiraihi.   

Abstract

OBJECTIVES: Bone marrow stromal cells (BMSCs) have been reported to improve movement deficit in adult rats with spinal cord injury (SCI). The purpose of this study is to determine the distribution of BMSCs in the spinal cord lesion of the contusion model of SCI.
METHODS: Laminectomy was carried out at L1 vertebra level and SCI was carried out using the weight drop method. BMSCs were isolated from adult rats, labeled with bromodeoxyuridine (BrdU) and administered intravenously to the rats 1 week after SCI, which were killed after 4 weeks. The non-treated animals were used as negative control, which showed cavitations of the spinal cord after 5 weeks of SCI. Rats in another group were killed immediately and used to study the hemorrhagic lesions. The volume densities (Vv) of the hemorrhage and cavitation were the highest at the site of direct trauma.
RESULTS: The numerical densities of the transmigrated cells per area (Nat) were as follows: 0.3 +/- 0.2, 3.9 +/- 0.4, 5.4 +/- 0.4, 8.4 +/- 0.5, 5.5 +/- 0.3, 3.6 +/- 0.3 and 0.4 +/- 0.2 at the end and the middle of the thoracic vertebra 13 (T13), the region between T13 and the first lumbar vertebra, the middle of L1, the region between L1 and L2, and the middle and the end of L2 vertebra, respectively. The distribution of Nat at the above regions was a Gaussian model. The volume densities of hemorrhage in the spinal cord taken from the above regions showed that hemorrhage with the highest volume density occurred at the impact site and the volume density declined as the samples taken were more distant from the impact site. DISCUSSION: The migration of BMSCs in the injured region depends on the amount of the hemorrhage and damage to blood vessels of the spinal cord.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17427270     DOI: 10.1179/016164107X165642

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  7 in total

1.  Microglial activation in rat experimental spinal cord injury model.

Authors:  Alireza Abdanipour; Taki Tiraihi; Taher Taheri; Hadi Kazemi
Journal:  Iran Biomed J       Date:  2013

2.  Effects of valproic acid, a histone deacetylase inhibitor, on improvement of locomotor function in rat spinal cord injury based on epigenetic science.

Authors:  Alireza Abdanipour; Hermann J Schluesener; Taki Tiraihi
Journal:  Iran Biomed J       Date:  2012

Review 3.  A systematic review of cellular transplantation therapies for spinal cord injury.

Authors:  Wolfram Tetzlaff; Elena B Okon; Soheila Karimi-Abdolrezaee; Caitlin E Hill; Joseph S Sparling; Jason R Plemel; Ward T Plunet; Eve C Tsai; Darryl Baptiste; Laura J Smithson; Michael D Kawaja; Michael G Fehlings; Brian K Kwon
Journal:  J Neurotrauma       Date:  2010-04-20       Impact factor: 5.269

Review 4.  Cell therapy for spinal cord regeneration.

Authors:  Stephanie M Willerth; Shelly E Sakiyama-Elbert
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

5.  Decreased GFAP expression and improved functional recovery in contused spinal cord of rats following valproic acid therapy.

Authors:  Marzieh Darvishi; Taki Tiraihi; Seyed A Mesbah-Namin; AliReza Delshad; Taher Taheri
Journal:  Neurochem Res       Date:  2014-09-10       Impact factor: 3.996

6.  Preparation of an acellular spinal cord scaffold to improve its biological properties.

Authors:  Hui Xing; Hong Yin; Chao Sun; Xianjun Ren; Yongyang Tian; Miao Yu; Tao Jiang
Journal:  Mol Med Rep       Date:  2019-06-06       Impact factor: 2.952

7.  Intraspinal transplantation of motoneuron-like cell combined with delivery of polymer-based glial cell line-derived neurotrophic factor for repair of spinal cord contusion injury.

Authors:  Alireza Abdanipour; Taki Tiraihi; Taher Taheri
Journal:  Neural Regen Res       Date:  2014-05-15       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.